HALO: Pangali rega marang bathi tumrap wutah halozyme.com

Halozyme Therapeutics (HALO) revenues are based on royalties from the use of the ENHANZE system, which, combined with the absence of geopolitical risks in Western markets, ensures stability. The PEG ratio captures the current valuation trend, where a metric value of 0.23 confirms the potential. Licensing alliances with pharma behemoths are accelerating the adoption of subcutaneous therapy, expanding oncology treatment capabilities.

Rasio rega marang bathi tumrap wutah: Halozyme Therapeutics, Inc. (HALO) kanggo 04.07.2022 - 15.11.2026

Rincian analitis perusahaan Halozyme (HALO)

- rega saham lan konsensus proyeksi valuasi:

Bagan owah-owahan rega Halozyme Inc.|HALO - Prakiraan konsensus analis

- informasi kapitalisasi pasar:

Biji pasar Halozyme Therapeutics, Inc.|HALO - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- indikator nilai buku ekuitas:

Nilai Buku saben Saham Halozyme|HALO - Nilai Buku Perusahaan|Nilai Pasar marang Nilai Buku halozyme.com|HALO - Total Aset Perusahaan

- rincian struktur utang lan likuiditas bisnis:

- indikator profitabilitas perusahaan lan kelipatan valuasi:

HALO - Penghasilan resik|Bathi forward Halozyme Therapeutics|HALO - Koefisien rega marang bathi|Rasio prakiraan rega marang bathi halozyme.com|HALO - Rasio rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Halozyme Corp|HALO - Bathi operasional EBITDA|Bathi resik saben siji saham sajrone rolas wulan pungkasan Halozyme|HALO - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan halozyme.com|HALO - Wutah bathi resik saben saham ing taun iki|Proyeksi tambahing bathi saben saham ing taun ngarep Halozyme Therapeutics

- data total pendapatan lan volume dodolan:

HALO - Pendapatan lan volume dodolan|Pendapatan mangsa ngarep perusahaan Halozyme Inc.|HALO - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Halozyme|HALO - Wutah dodolan YoY sajrone rolas wulan kepungkur

Analisis umum perusahaan:HALO Halozyme Corp

Amidst fierce patent battles in the drug delivery niche, Halozyme Therapeutics (HALO) risks losing contracts due to the budgets of biotech behemoths. This indicator for identifying undervalued growth companies compares the current P/E ratio with earnings growth rates, allowing for the daily tracking of an asset's market undervaluation when the value falls below one, which is critical for the timely detection of a trend reversal.

Pesaing Halozyme Therapeutics